AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach